Conexiant’s news site is now MDSpire News. Learn more
Advertisement
Roving Reporter Asks: How Is Cell and Gene Therapy Manufacturing Becoming More Scalable?
IBTV speaks with industry leaders at ASGCT 2026 about the technologies, processes, and manufacturing strategies helping advanced therapies progress toward commercial scale
To explore innovations impacting the scalability, consistency, and commercial readiness of cell and gene therapy manufacturing.
Approach:
Industry Insights: Experts from various companies discuss advancements and challenges in manufacturing cell and gene therapies.
Key Findings:
Manufacturing is a significant barrier to the widespread adoption of cell and gene therapies.
Stable cell lines, process intensification, AI-driven process modeling, operational excellence, and quality-by-design are key tools for increasing output.
Flexible manufacturing models and stronger analytical technologies can help adapt production to various therapeutic modalities.
Conclusion:
The insights highlight the ongoing challenges and innovations in the manufacturing sector of cell and gene therapies.
